Natera (NTRA) Projected to Post Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is expected to be announcing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.53) per share and revenue of $616.9880 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. The firm had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same period last year, the business posted ($0.41) EPS. On average, analysts expect Natera to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Natera Stock Performance

Shares of NTRA stock traded up $5.67 on Wednesday, reaching $212.44. The stock had a trading volume of 76,675 shares, compared to its average volume of 1,207,905. The stock has a market cap of $30.23 billion, a P/E ratio of -138.12 and a beta of 1.57. Natera has a 1 year low of $131.81 and a 1 year high of $256.36. The company has a 50 day simple moving average of $201.91 and a 200 day simple moving average of $214.51.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Analyst support: Multiple firms have recent buy/outperform calls and upgrades (William Blair coverage; Wall Street Zen upgraded to Buy), supporting upside versus peers and the consensus target near $253.
• Positive Sentiment: Institutional demand: Large institutional positions were added/expanded in recent quarters (e.g., Robinhood Asset Management new stake; JPMorgan substantially increased its holding), signaling long?term investor confidence.
• Neutral Sentiment: CEO sale under 10b5?1: CEO Steven Leonard Chapman sold 902 shares at ~$206.16 to cover tax obligations; disclosed on Form 4. These trades are pre?arranged and routine. SEC Form 4
• Neutral Sentiment: Multiple insider 10b5?1 sales: CFO Michael Brophy, John Fesko and Solomon Moshkevich sold shares (small percentages of their holdings) at ~206–210 to cover tax withholdings; filings indicate pre?arranged plans, so these are typically neutral for fundamentals. Insider Trades Summary
• Negative Sentiment: Bearish analyst notes: A few outlets remain negative — Weiss Ratings reaffirmed a “sell (d?)” and Morgan Stanley trimmed its target from $265 to $250 — which may cap near?term upside despite analyst majority leaning Buy.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Wells Fargo & Company raised their price target on Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Robert W. Baird raised their price target on Natera from $239.00 to $257.00 and gave the stock an “outperform” rating in a research note on Friday, February 27th. Wall Street Zen upgraded Natera from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. Finally, Citigroup assumed coverage on Natera in a research note on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.47.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 5,838 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $204.14, for a total value of $1,191,769.32. Following the transaction, the chief executive officer directly owned 150,769 shares of the company’s stock, valued at approximately $30,777,983.66. This trade represents a 3.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 1,688 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $204.10, for a total value of $344,520.80. Following the completion of the transaction, the insider directly owned 187,511 shares in the company, valued at approximately $38,270,995.10. This represents a 0.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 38,266 shares of company stock valued at $7,747,808 in the last 90 days. 5.63% of the stock is owned by company insiders.

Hedge Funds Weigh In On Natera

Institutional investors have recently bought and sold shares of the stock. Horizon Investments LLC bought a new position in Natera in the 3rd quarter worth $32,000. Bank of Jackson Hole Trust raised its holdings in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares during the period. Kemnay Advisory Services Inc. bought a new position in Natera in the 4th quarter worth $39,000. Greenline Wealth Management LLC bought a new position in Natera in the 4th quarter worth $41,000. Finally, HM Payson & Co. raised its holdings in Natera by 214.9% in the 4th quarter. HM Payson & Co. now owns 211 shares of the medical research company’s stock worth $48,000 after purchasing an additional 144 shares during the period. 99.90% of the stock is owned by institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.